Tools for identifying, treating, monitoring, and preventing skin toxicities
April 1, 2011|The Journal of Community and Supportive Oncology
Author and Disclosure Information
From the 6th Annual Community Oncology Conference
Juggling clinical advances and sweeping changes in practice
The following reports are based on presentations at the 6th Annual Community Oncology Conference held in Las Vegas, February 25–26, 2011. Additional presentations will be featured in a supplement to an upcoming issue of Community Oncology. The conference is presented annually by this journal.
On the other hand, four trials have shown that high-potency topical corticosteroids, such as mometasone cream, used prophylactically are effective for reducing symptoms of radiation dermatitis. When patients develop severe radiation dermatitis and moist desquamation, “Staphylococcus aureus is uniformly present, so consider culturing that area,” he recommended.
Dr. Lacouture reported being a consultant to Genentech, Hana Biosciences, OSI Pharmaceuticals, Amgen, GlaxoSmithKline, ImClone Systems, Bristol Myers-Squibb, Onyx Pharmaceuticals, Lindi Skin, and Bayer Pharmaceuticals.
